Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775398 · ClinicalTrials.gov registry record
Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 553
- Enrollment target
NCT00775398: Completed study, sponsored by Pfizer.
NCT00775398 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 553 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00775398 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 553 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of possible exposure to THROMBIN JMI® on activated partial thromboplastin time (aPTT) at 48 hours post surgery in subjects with likelihood of prior exposure to THROMBIN JMI® within the past 4 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-11 |
What the finished NCT00775398 record still lists
NCT00775398 is an observational study that tracks outcomes without assigning an intervention. The registered 553 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00775398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00775398 about?
NCT00775398 is a clinical study titled "Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.". The purpose of this study is to assess the effect of possible exposure to THROMBIN JMI® on activated partial thromboplastin time (aPTT) at 48 hours post surgery in subjects with likelihood of prior exposure to THROMBIN JMI® within the past 4 years.
What is the current status of trial NCT00775398?
This trial is currently completed. The enrollment target is 553 participants. The study started on 2008-11. Estimated completion is 2009-11.
Who is sponsoring clinical trial NCT00775398?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia